Provided by Tiger Trade Technology Pte. Ltd.

ALX Oncology Holdings

1.39
+0.04002.96%
Post-market: 1.390.00000.00%19:30 EDT
Volume:1.34M
Turnover:1.86M
Market Cap:192.21M
PE:-1.21
High:1.46
Open:1.34
Low:1.31
Close:1.35
52wk High:2.66
52wk Low:1.05
Shares:138.28M
Float Shares:94.74M
Volume Ratio:0.91
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1500
EPS(LYR):-1.9000
ROE:-80.65%
ROA:-40.40%
PB:1.41
PE(LYR):-0.73

Loading ...

ALX Oncology Says Phase 2 ASPEN-06 Study Shows 40.3% Response Rate for Evorpacept Combo in HER2-Positive Gastric Cancer

Reuters
·
Sep 28

H.C. Wainwright Sticks to Their Buy Rating for ALX Oncology Holdings (ALXO)

TIPRANKS
·
Sep 22

Top Premarket Decliners

MT Newswires Live
·
Sep 18

ALX Oncology to Present at Wells Fargo, Cantor and H.C. Wainwright Investor Conferences

Reuters
·
Sep 02

ALX Oncology Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

ALX Oncology Holdings Inc Expected to Post a Loss of 15 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Soligenix Q2 Net Loss Narrows as R&D Expenses Fall

Reuters
·
Aug 07

Analysts Have Conflicting Sentiments on These Healthcare Companies: Astrana Health (ASTH) and ALX Oncology Holdings (ALXO)

TIPRANKS
·
Aug 07

Zentalis Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

NextCure Q2 Net Loss Narrows on Lower Expenses

Reuters
·
Aug 07

Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline

Reuters
·
Aug 07

INmune Bio Q2 Net Loss Narrows on Lower Impairment Charges

Reuters
·
Aug 07

ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate

Benzinga Earnings
·
Aug 06

ALX Oncology Q2 FY26 GAAP Net Loss Narrows to $18 Million; R&D Expenses Fall 27.2% to $13.1 Million

Reuters
·
Aug 06

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 06

ALX Oncology Q2 EPS USD -0.13

THOMSON REUTERS
·
Aug 06

ALX Oncology Grants General Counsel Listgarten Option for 500,000 Shares at $2.20 Each

Reuters
·
Jul 01

ALX Oncology Reports Inducement Grant as Permitted by the NASDAQ Listing Rules

THOMSON REUTERS
·
Jul 01

ALX Oncology Names Scott Garland Board Chairman, Replacing Co-founder Corey Goodman

Reuters
·
Jun 30

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

THOMSON REUTERS
·
Jun 30